PubRank

Ralf Gold

Author PubWeight™ 212.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008 3.68
2 Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008 3.67
3 Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005 3.42
4 Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011 3.38
5 MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014 3.27
6 Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012 2.90
7 New glucocorticoids on the horizon: repress, don't activate! J Rheumatol 2005 2.70
8 Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011 2.44
9 Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013 2.23
10 Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005 2.20
11 Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011 2.19
12 Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004 2.11
13 L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013 2.02
14 Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol 2013 2.00
15 CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002 1.91
16 Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005 1.79
17 Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology 2012 1.78
18 Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 2012 1.66
19 Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009 1.63
20 Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 2009 1.56
21 Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 2002 1.53
22 Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010 1.52
23 Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007 1.52
24 Towards individualised multiple-sclerosis therapy. Lancet Neurol 2005 1.46
25 Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012 1.46
26 Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One 2009 1.44
27 Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007 1.42
28 Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012 1.41
29 Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 2011 1.33
30 Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013 1.30
31 Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009 1.27
32 Intra- and internerve cross-sectional area variability: new ultrasound measures. Muscle Nerve 2012 1.25
33 Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008 1.22
34 Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005 1.20
35 Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 2008 1.20
36 Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006 1.17
37 Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol 2013 1.17
38 Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 2011 1.17
39 Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) 2010 1.13
40 Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010 1.11
41 Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003 1.11
42 Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 2012 1.11
43 Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 2011 1.10
44 Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004 1.09
45 Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 2008 1.08
46 Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol 2012 1.07
47 Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007 1.05
48 Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011 1.05
49 Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord 2011 1.05
50 Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med 2013 1.04
51 Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 2011 1.03
52 Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem Cell Biol 2002 1.02
53 Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol 2002 1.02
54 Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011 1.02
55 Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci 2012 1.02
56 Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011 1.01
57 Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003 1.01
58 Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta. Glia 2003 1.01
59 The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 2010 1.01
60 Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord 2013 1.01
61 EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol Dis 2005 0.99
62 Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014 0.99
63 Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography. J Neurol 2014 0.99
64 Huntington's disease as caused by 34 CAG repeats. Mov Disord 2008 0.99
65 Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol 2014 0.97
66 Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008 0.97
67 Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008 0.97
68 MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J Clin Invest 2015 0.97
69 Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler 2013 0.96
70 Induction of experimental autoimmune encephalomyelitis in transgenic mice expressing ovalbumin in oligodendrocytes. Eur J Immunol 2006 0.96
71 Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J Mol Med (Berl) 2005 0.96
72 Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010 0.96
73 IL-17 production by thymocytes upon CD3 stimulation and costimulation with microbial factors. Cytokine 2006 0.95
74 IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J Neuroimmunol 2008 0.93
75 Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012 0.93
76 Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006 0.93
77 Time processing in Huntington's disease: a group-control study. PLoS One 2007 0.93
78 Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010 0.93
79 Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 2012 0.93
80 Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011 0.92
81 Error processing in Huntington's disease. PLoS One 2006 0.92
82 A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 2005 0.91
83 Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease? Neuropsychologia 2007 0.91
84 Improving the default data analysis workflow for large autoimmune biomarker discovery studies with ProtoArrays. Proteomics 2013 0.91
85 alpha4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol 2008 0.90
86 Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008 0.90
87 Response inhibition in Huntington's disease-a study using ERPs and sLORETA. Neuropsychologia 2007 0.90
88 Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep 2013 0.90
89 Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006 0.90
90 Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult Scler 2010 0.89
91 Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J Immunol 2008 0.89
92 The PLPp-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17-producing cells. Cytokine 2007 0.89
93 Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death. Brain 2012 0.89
94 Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol 2011 0.88
95 Enhanced glucocorticoid receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune responses. Am J Pathol 2007 0.88
96 Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother 2013 0.88
97 Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002 0.87
98 Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 2002 0.87
99 Assessment of lesion evolution in experimental autoimmune neuritis by gadofluorine M-enhanced MR neurography. Exp Neurol 2005 0.87
100 Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Arch Immunol Ther Exp (Warsz) 2013 0.87
101 Inflammation modulates anxiety in an animal model of multiple sclerosis. Behav Brain Res 2011 0.87
102 Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 2008 0.87
103 Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev Neurother 2006 0.86
104 Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol 2011 0.86
105 In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging. J Neuroimmunol 2004 0.86
106 Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. J Neurol Sci 2012 0.86
107 Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One 2009 0.86
108 Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology 2013 0.86
109 Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2008 0.86
110 Plasmapheresis for neurological disorders. Expert Rev Neurother 2009 0.85
111 Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother 2008 0.85
112 Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J Neuroinflammation 2012 0.85
113 Spotlight on fumarates. Int MS J 2008 0.85
114 Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002 0.85
115 Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2009 0.85
116 Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol 2010 0.85
117 Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci 2011 0.85
118 Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 2005 0.84
119 Experimental pneumococcal meningitis: impaired clearance of bacteria from the blood due to increased apoptosis in the spleen in Bcl-2-deficient mice. Infect Immun 2004 0.84
120 Teaching Video NeuroImages: spinal and bulbar muscular atrophy mimicking essential tremor. Neurology 2012 0.84
121 MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J Clin Invest 2015 0.84
122 Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord 2002 0.84
123 The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003 0.84
124 Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol 2008 0.83
125 Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol 2011 0.83
126 Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study. J Neurol 2003 0.83
127 Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol 2008 0.83
128 Symptomatic hyperekplexia in a patient with multiple sclerosis. Neurology 2002 0.83
129 Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis. Arch Neurol 2009 0.83
130 Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol 2013 0.83
131 New Glucocorticoids on the Horizon: Repress, Don't Activate! J Rheumatol 2005 0.82
132 Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis. J Neurophysiol 2008 0.82
133 Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 2008 0.82
134 Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 2007 0.82
135 Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol 2011 0.82
136 Differential expression of BDNF mRNA splice variants in mouse brain and immune cells. J Neuroimmunol 2006 0.82
137 Downregulation of transforming growth factor-beta2 facilitates inflammation in the central nervous system by reciprocal astrocyte/microglia interactions. J Neuropathol Exp Neurol 2007 0.81
138 Tolerance induction by intrathymic expression of P0. J Immunol 2004 0.81
139 Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. J Cardiovasc Pharmacol 2003 0.81
140 Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation. Am J Pathol 2007 0.81
141 The fumaric acid ester BG-12: a new option in MS therapy. Expert Rev Neurother 2013 0.81
142 Models of monocytic invasion into glioma cell aggregates. Anticancer Res 2006 0.81
143 Increased MS relapse rate during assisted reproduction technique. J Neurol 2008 0.81
144 Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability. Neurogenetics 2015 0.81
145 Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol 2014 0.81
146 Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol 2007 0.80
147 Correlation of nerve ultrasound, electrophysiological, and clinical findings in post Guillain-Barré syndrome. J Peripher Nerv Syst 2013 0.80
148 Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice. J Neurol Sci 2005 0.80
149 Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol 2014 0.80
150 An electrophysiologic approach to quantify impaired synaptic transmission and plasticity in experimental autoimmune encephalomyelitis. J Neuroimmunol 2013 0.80
151 Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination. J Neuroimmunol 2012 0.80
152 Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol 2010 0.79
153 A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 2011 0.79
154 1H-magnetic resonance spectroscopy in diffuse and focal cervical cord lesions in multiple sclerosis. Eur Radiol 2013 0.79
155 Unusual Charcot-Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin protein zero. Muscle Nerve 2010 0.79
156 Managing MS in a changing treatment landscape. J Neurol 2011 0.79
157 Multifocal motor neuropathy: correlation of nerve ultrasound, electrophysiological, and clinical findings. J Peripher Nerv Syst 2014 0.78
158 Advancing therapeutic options in multiple sclerosis with neuroprotective properties. J Neural Transm (Vienna) 2013 0.78
159 Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease. Eur J Nucl Med Mol Imaging 2014 0.78
160 [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]. Med Klin (Munich) 2010 0.78
161 Antigen therapy of experimental autoimmune encephalomyelitis selectively induces apoptosis of pathogenic T cells. J Neuroimmunol 2007 0.78
162 Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. J Histochem Cytochem 2003 0.78
163 Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 2011 0.78
164 Cross sectional area reference values for sonography of peripheral nerves and brachial plexus. Clin Neurophysiol 2013 0.78
165 The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol 2008 0.77
166 Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Mol Neurodegener 2014 0.77
167 Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol 2002 0.77
168 Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler 2012 0.77
169 MBP-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. J Immunol 2004 0.77
170 Modulation of experimental autoimmune encephalomyelitis by administration of cells expressing antigenic peptide covalently linked to MHC class II. J Neuroimmunol 2004 0.77
171 Neuropsychological/-psychiatric deficits in immune-mediated neuropathies. J Neurol 2007 0.77
172 Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. J Neurol 2003 0.77
173 Review of laquinimod and its therapeutic potential in multiple sclerosis. Expert Opin Pharmacother 2013 0.77
174 Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol 2010 0.77
175 Isolated ZIC4 antibodies in paraneoplastic cerebellar syndrome with an underlying ovarian tumor. Arch Neurol 2011 0.77
176 Sonographic detection of bilateral striopallidodentate calcinosis. J Neurol 2009 0.77
177 Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior. Behav Brain Res 2012 0.76
178 Permanent effector phenotype of neuroantigen-specific T cells acquired in the central nervous system during experimental allergic encephalomyelitis. Neurosci Lett 2005 0.76
179 Type III systemic allergic reaction to natalizumab. Arch Neurol 2008 0.76
180 Evaluation of basal ganglia, brainstem raphe and ventricles in bipolar disorder by transcranial sonography. Psychiatry Res 2011 0.76
181 Phagocytosis of apoptotic inflammatory cells downregulates microglial chemoattractive function and migration of encephalitogenic T cells. J Neurosci Res 2006 0.76
182 Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. J Clin Immunol 2012 0.76
183 Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. Immunity 2016 0.76
184 Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease. J Neuroimmune Pharmacol 2014 0.75
185 Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2012 0.75
186 Interferon beta, birth weight and pregnancy in multiple sclerosis. J Neurol 2009 0.75
187 Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 2008 0.75
188 Many roads lead to Rome: heterogeneity among encephalitogenic T cell clones. J Neuroimmunol 2007 0.75
189 Ventricular tachycardia during basilar-type migraine attack. Ther Adv Neurol Disord 2013 0.75
190 Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2011 0.75
191 Sphingosine-1-phosphate and its receptors as a possible therapeutic target in autoimmune diseases of the nervous system. J Neuroimmunol 2009 0.75
192 Detection of patient subgroups with differential expression in omics data: a comprehensive comparison of univariate measures. PLoS One 2013 0.75
193 Ascending myelitis. BMJ Case Rep 2009 0.75
194 Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2012 0.75
195 Devic disease: translational medicine at work. Neurology 2014 0.75
196 Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am J Cardiol 2002 0.75
197 Remote changes in gene expression after autoimmune demyelination: grey matters. J Neuroimmunol 2008 0.75
198 Devic's disease: bridging the gap between laboratory and clinic. Brain 2002 0.75
199 Overcoming failure to repair demyelination in EAE: an important step towards neuroprotection in multiple sclerosis. J Neuroimmunol 2005 0.75
200 Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis? Exp Neurol 2009 0.75
201 Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach. J Neurol 2006 0.75
202 Discordant findings in color-coded duplex-sonography and magnetic resonance angiography in symptomatic internal carotid artery stenosis: implications for diagnostic work-up and early intervention. Ther Adv Neurol Disord 2010 0.75
203 The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation. Am J Pathol 2010 0.75
204 Genomic NGFB variation and multiple sclerosis in a case control study. BMC Med Genet 2008 0.75
205 Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 2012 0.75
206 Serum and cerebrospinal fluid concentrations of homoarginine, arginine, asymmetric and symmetric dimethylarginine, nitrite and nitrate in patients with multiple sclerosis and neuromyelitis optica. Amino Acids 2015 0.75
207 Effects of polyclonal immunoglobulins and other immunomodulatory agents on microglial phagocytosis of apoptotic inflammatory T-cells. J Neuroimmunol 2003 0.75
208 Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Clin Neurol Neurosurg 2011 0.75
209 Brainstem raphe alterations depicted by transcranial sonography do not result in serotonergic functional impairment. J Neuroimaging 2013 0.75
210 Clinical reasoning: a 48-year-old woman with recurrent headache, transient neurologic symptoms, and CSF pleocytosis. Neurology 2012 0.75
211 Wheels within wheels: multifocal autoimmune myelitis in a woman with Huntington's disease. J Neurol 2012 0.75
212 8th international congress of neuroimmunology. J Neuroimmunol 2007 0.75
213 Truncation of the neuritogenic peptide bP2(60-70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation. J Neuroimmunol 2002 0.75
214 Atypical occipital calcinosis in a Caucasian individual with probable diffuse neurofibrillary tangles with calcification. J Am Geriatr Soc 2014 0.75
215 [Multiple sclerosis: oral drugs]. MMW Fortschr Med 2013 0.75
216 Dagibatran Etexilate: Is There Any Need for Coagulation Monitoring After Initiation? Neurologist 2015 0.75
217 Transcranial sonography in obsessive-compulsive disorder. J Psychiatr Res 2013 0.75
218 Can pathological patterns be used to guide individualized multiple sclerosis therapy? Nat Clin Pract Neurol 2006 0.75
219 Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome. J Neurol 2006 0.75
220 Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler 2012 0.75
221 Recurrent trimethoprim-sulfamethoxazole-induced aseptic meningitis with associated ampicillin-induced myoclonic twitches
. Int J Clin Pharmacol Ther 2017 0.75
222 Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis. Int Immunopharmacol 2012 0.75
223 Teaching NeuroImages: sonographic "retrobulbar spot sign" in differentiating etiologies of sudden visual loss. Neurology 2014 0.75
224 Anti-GT1a IgG antibodies in a child with severe Guillain-Barré syndrome. Pediatr Neurol 2006 0.75
225 Correlation between frequency of microembolic signals and efficacy of antiplatelet therapy in symptomatic carotid disease. J Neuroimaging 2013 0.75
226 Clinical reasoning: a 48-year-old woman with progressive spastic-ataxic gait. Neurology 2013 0.75
227 The agony of choice: diagnosis of cervical artery dissection by means of duplexsonography or magnetic resonance imaging? Cerebrovasc Dis 2009 0.75